Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Common Equity (2016 - 2025)

Seres Therapeutics' Common Equity history spans 11 years, with the latest figure at $43.7 million for Q3 2025.

  • For Q3 2025, Common Equity rose 82.69% year-over-year to $43.7 million; the TTM value through Sep 2025 reached $43.7 million, up 82.69%, while the annual FY2024 figure was $13.8 million, 130.73% up from the prior year.
  • Common Equity for Q3 2025 was $43.7 million at Seres Therapeutics, up from $32.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $175.7 million in Q3 2021 and bottomed at -$87.1 million in Q2 2024.
  • The 5-year median for Common Equity is $23.9 million (2024), against an average of $35.1 million.
  • The largest annual shift saw Common Equity surged 333.1% in 2021 before it plummeted 515.99% in 2023.
  • A 5-year view of Common Equity shows it stood at $131.5 million in 2021, then crashed by 91.8% to $10.8 million in 2022, then tumbled by 515.99% to -$44.9 million in 2023, then skyrocketed by 130.73% to $13.8 million in 2024, then surged by 217.01% to $43.7 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Common Equity are $43.7 million (Q3 2025), $32.9 million (Q2 2025), and $50.5 million (Q1 2025).